Screener
Precigen PGEN R&D
R&D at other companies
Other financials
Where this comes from
Reported directly by Precigen in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Precigen’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356090-26-000017
| (Amounts in thousands, except share and per share data) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total revenues | 23,252 | 1,341 |
| Operating Expenses | ||
| Cost of products and services | 2,559 | 1,100 |
| Research and development | 5,638 | 10,478 |
| Selling, general and administrative | 21,049 | 12,359 |
| Total operating expenses | 29,246 | 23,937 |
| Operating loss | (5,994) | (22,596) |
| Other Income (Expense), Net |
Item 1. Condensed Consolidated Financial Statements
FAQ
- What is Precigen's R&D?
- Precigen (PGEN) reported R&D of $5.64M in Q1 2026.
- How has Precigen's R&D changed year-over-year?
- Precigen's R&D decreased by 46.2% year-over-year, from $10.48M to $5.64M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Precigen's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude